TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Institut du Cancer de Montpellier - Val d'Aurelle
Bristol-Myers Squibb
Bristol-Myers Squibb
NuCana plc
Gilead Sciences
Thomas Jefferson University
NuCana plc
HiberCell, Inc.
Merck Sharp & Dohme LLC
EpicentRx, Inc.
Academic and Community Cancer Research United
Vanderbilt-Ingram Cancer Center
NantBioScience, Inc.
Federation Francophone de Cancerologie Digestive
Kyowa Kirin Co., Ltd.
Pfizer
Sumitomo Pharma America, Inc.
Eisai Inc.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Institut Bergonié
Academic and Community Cancer Research United
NSABP Foundation Inc
GERCOR - Multidisciplinary Oncology Cooperative Group
Nektar Therapeutics
Grupo Espanol Multidisciplinario del Cancer Digestivo
Daiichi Sankyo
Fox Chase Cancer Center
AbbVie
SillaJen, Inc.
UNC Lineberger Comprehensive Cancer Center
SWOG Cancer Research Network
M.D. Anderson Cancer Center
Eli Lilly and Company
Gilead Sciences
Alliance for Clinical Trials in Oncology
Daiichi Sankyo
Radiation Therapy Oncology Group
Eli Lilly and Company
Medical University of Vienna
mAbxience Research S.L.
University of Pittsburgh
Northwestern University
Gilead Sciences
Symphogen A/S
Hoffmann-La Roche
Pfizer
Amgen